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Abstract
To determine the association between individual substances of abuse and antiretroviral adherence, 
analyses require a large sample assessed using electronic data monitoring (EDM). In this analysis, 
EDM data from 1636 participants in 12 U.S. adherence-focused studies were analyzed to 
determine the associations between recent use of various substances and adherence during the 
preceding four weeks. In bivariate analyses comparing adherence among patients who had used a 
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specific substance to those who had not, adherence was significantly lower among those who had 
recently used cocaine, other stimulants or heroin but not among those who had used cannabis or 
alcohol. In multivariate analyses controlling for sociodemographics, amount of alcohol use and 
recent use of any alcohol, cocaine, other stimulants and heroin each was significantly negatively 
associated with adherence. The significant associations of cocaine, other stimulants, heroin, and 
alcohol use with adherence suggest that these are important substances to target with adherence-
focused interventions.
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INTRODUCTION
Substance-using individuals living with HIV/AIDS become ill more rapidly than those who 
do not use substances for many reasons including delays in initiating highly active 
antiretroviral therapy (HAART) (1, 2), a disproportionately high likelihood of dropping out 
of treatment (3) and addiction-related comorbidities such as cognitive impairment (4).
Sub-optimal adherence to HAART is a particularly important reason that drug users have 
worse viral load outcomes after beginning HAART (5). Sub-optimal adherence to HAART 
has been consistently associated with worse outcomes (6–9), with the specific thresholds at 
which non-adherence worsens outcomes depending on the regimen and resistance profile of 
the HIV virus (10, 11).
Identifying which substances may interfere with adherence to HAART and which do not is 
important for informing the best ways to improve adherence. Taken separately, studies 
conducted using electronic data monitoring (EDM) have modest statistical power to 
delineate the extent to which specific substances are independently associated with non-
adherence in multivariate analyses that control for factors differentiating people who use 
substances from those who do not. Reviews of the literature linking substance use to non-
adherence to HAART (12, 13) identify a limited number of studies using EDM (14–20).
Studies using EDM are particularly valuable when considering the association between use 
of specific substances and adherence because drug users appear disproportionately prone to 
self-report better adherence than is indicated by objective measures of adherence. In an 
analysis of people whose self-report was discrepant from electronically-measured 
adherence, recent substance use was associated with discrepant reporting (21). In a meta-
analysis of the impact of alcohol use on adherence, studies that used EDM or other objective 
measures of adherence detected more alcohol-related lowering of adherence than studies 
relying on self-report (22).
In a review of published studies of HAART adherence among substance abusers, including 
those studies using self-report to measure adherence, only a limited number of the studies 
examined specific substances separately (12), and fewer still specified that the use of the 
substances had been recent. A study of 148 HIV-infected individuals in Los Angeles 
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described an association between illicit drug use, but not alcohol use, and lower adherence 
(17). A contradictory finding from 201 former drug users who were starting a new HAART 
regimen found worse adherence among people who reported recent use of either alcohol or 
marijuana, but not among those who had used any other illicit drug (cocaine, heroin or 
methamphetamine) (18). A study of 85 current and former drug users prescribed methadone 
found a strong link between cocaine use and non-adherence but no significant effect of 
either heroin or alcohol use on adherence (14). A study in Los Angeles identified alcohol 
use and use of any illicit drug as independent predictors of non-adherence (19).
To better understand the findings from these separate studies, we examined the effect of 
individual substances of abuse on adherence using pooled data from the MACH14 cohort 
(Multisite Adherence Collaboration in HIV http://mach14.med.ucla.edu/). This study 




As previously described (23), data were collected and pooled from 16 studies conducted at 
14 sites across 12 states in the United States to compile the MACH14 cohort. Each study 
collected adherence data with EDM (e.g. MEMS™, Aardex) to estimate participants’ 
adherence to antiretroviral medication. This cross-sectional analysis used data from the first 
time-point of each study at which participants had been asked about their substance use and 
had EDM data for the preceding four weeks.
Measures
Different study sites had asked about substance use with different formats and over different 
time frames--“How many days in the last 7 did you drink alcohol?” “last 14 days,” etc. To 
derive a measure that could be extracted from different questions asked at different sites, 
substance use was standardized across sites as the proportion of measured days having used 
a given substance. For alcohol, the assessed timeframes ranged from 7 to 90 days with an 
average timeframe of 38.1 preceding days. The timeframes used were approximately the 
same for other substances.
Because instruments assessed substance use in the days and weeks preceding the survey 
administration, our estimates of HAART adherence were based on data collected during the 
four weeks preceding those same surveys. Adherence was measured by dividing the total 
number of openings by the number of prescribed doses for each medication. Adherence to 
any medication was capped at 100%. Adherence for a patient on multiple antiretrovirals was 
calculated by averaging the adherence to all measured antiretrovirals.
Data Analysis
The relationship between adherence and use of individual substances was analyzed in a 
series of bivariate analyses, and then in a multivariate analysis that controlled for potential 
confounding differences between people who did and did not use substances.
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As expected, the distribution of proportion of days using each substance except alcohol was 
significantly positively skewed with a preponderance of zero values. Therefore, a series of 
bivariate analyses was conducted to determine the relationship between adherence and a 
dichotomous measure of “any use” or “not any use” during the measured timeframe. To 
determine alcohol’s effects, bivariate analyses compared alcohol abstainers to people who 
had used any alcohol, and to people who drank every day. Because some substances have 
been associated with non-adherence in women but not in men (24), a follow-up regression 
analysis was conducted to estimate the interaction between gender and substance use.
Next, a series of multivariate analyses were run to determine the effect of each substance 
after controlling for sociodemographic factors. To determine the sociodemographics to use 
for these analyses, potential covariates were entered into a regression model to determine 
which significantly (p<.05) predicted adherence. Those significantly associated with 
adherence were retained as covariates for all subsequent analyses. In these subsequent 
regressions, successive models were tested in which each substance was individually added 
to and withdrawn from a model with the sociodemographic variables. Two regressions were 
run for each substance: one with substance use as a dichotomous measure of “any use” and 
one with substance use as a continuous measure of the proportion of days of use.
A final multivariate regression model estimated the unique effect of each substance when all 
other substances of abuse were included in the model. Alpha was set at .05 for all analyses.
Sampling for Analyses
Data were drawn from twelve of the MACH14 sites that had adequate substance use and 
adherence data for the analyses, with sites contributing a mean of 136 participants (range 
between 16 and 257). The initial bivariate analysis used data from 1636 participants, and the 
multivariate analysis was restricted to the 1311 participants who also had data for all the 
covariates in these analyses.
RESULTS
Baseline Characteristics
Using data from the full (n=1636) sample, participants’ average age was 41.9 (S.D. 8.1), and 
racial/ethnic breakdown included 31.3% Caucasians, 46.2% African Americans, and 12.7% 
Hispanics. Altogether, 67.9% were male, and 40.1% were men who have sex with men 
(MSM). Many participants were indigent in that 80.0% had a total household income less 
than $20,000 per year and 57.3% had annual incomes below $10,000. Only 27.7% were 
employed.
A relatively high percentage reported recent alcohol use (47.7%) but only 1.8% reported 
drinking every day. The order of prevalence for recent use of illicit drugs was cannabis 
(23.6% from n of 1354 with this measure); heroin (15.3%, n=1279); cocaine (10.6%, 
n=1431); and other stimulants (4.1%, n=1216). The percentage of the combined sample 
recently using any illicit drug was 38.1% (n=1436), using any illicit drug or alcohol was 
60.0% (n=1568), and using more than one substance was 22.1% (n=1568).
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Mean EDM-measured adherence during the four weeks preceding the substance use 
assessment was 69.3% (S.D.=33.4%) and 23.5% of participants had taken 100% of their 
monitored antiretrovirals.
Bivariate Analyses
As shown in Figure 1, bivariate analyses revealed that for cocaine, other stimulants, or 
heroin, people who had used the substance had significantly lower adherence than people 
who had not used the substance. People who drank any alcohol did not have significantly 
lower adherence than people who had abstained from alcohol, and those people who drank 
alcohol every day had no lower adherence than those who did not drink at all (27 daily 
alcohol users and 774 abstainers; 62.1% vs.70.6% adherence, t=1.29, p= 0.196).
To determine if the lack of main effects of any alcohol or of cannabis masked an effect 
limited to men or women, an analysis of the interaction of gender by substance of use was 
conducted. A main effect of gender was noted, with men more adherent than women, but 
there was no significant interaction between gender and either use of any alcohol or use of 
any cannabis.
Multivariate Analyses of Individual Substances
The model for determining the contribution of each substance after adjusting for other 
factors associated with adherence was created by regressing adherence on socio-
demographic factors: age, gender, race, education (less than high school, high school, and 
above high school), employment (yes/no), and MSM (Men who have Sex with Men). 
Caucasian was the reference group for race. Factors that were significantly associated with 
adherence were retained and are as follows (with regression estimates in parentheses): 
African American (−0.050), Hispanic (−0.080), Asian American (0.037), and MSM (0.066). 
This model accounted for 2.8% of the variance in adherence.
A dichotomous measure of use (vs. no use) of each of the substances was then added in 
separate regression models controlling for these indicators of race and sexual practice. In 
these analyses (Table 1, column 3), any use of alcohol, cocaine, heroin, or stimulants was 
associated with lower adherence.
These multivariate models were then run again, substituting the continuous measures of the 
proportion days participants used each substance for the dichotomous measures of any use of 
each substance used in the prior analysis. Independent variables reflecting proportion days 
using alcohol, cocaine, or heroin each were significantly negatively associated with 
adherence in the regressions controlling for socio-demographics (shown in Table 1, columns 
6–8); proportion days using cannabis and stimulants were not.
Multivariate Analyses Including All Substances
A multivariate analysis with all substances included in the same model was run to consider 
the extent to which substances independently impacted adherence. In the model with all 
substances and significant demographic variables, only any use of heroin (p=.03) was 
significantly associated with adherence.
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The finding of significant associations between adherence and recent use of cocaine, heroin, 
other stimulants, or alcohol replicates those found in smaller datasets. It is noteworthy that 
these effects emerge with this dataset, the largest dataset with measures of both use of 
individual substances and electronic measures of medication-taking. This study’s findings 
make it more likely that prior reports do not represent spurious associations between drug 
use and adherence, or associations that only apply to particular study settings.
However, overall effects were small, with even significant measures of substance use 
accounting for only 1% of the variance in adherence. The fact that data were pooled from 
many sites likely diluted the effect of drugs at particular sites. The regional variation in 
which drugs are popular has been well-reported, and pooling data from areas in which 
different substances are used (e.g. cocaine in New York and stimulants in California) dilutes 
the effect of each in the combined data.
Although small, the negative associations between recent cocaine or heroin use and 
adherence were consistent across our analyses, and are consistent with other studies that 
found lower adherence among people who recently used cocaine or heroin. Most studies 
have reported a link between stimulant use and non-adherence, and extensive qualitative 
data have described the disruptive effects of stimulant use on medication-taking (25). 
Alcohol use has also been associated with worse self-reported adherence in a meta-analysis 
of data from a variety of populations (22).
The lack of an association between cannabis use and adherence in this study is consistent 
with cannabis’ lack of effect on self-reported adherence in a large study of 764 patients at an 
inner city clinic (26). There are other settings in which cannabis use is somewhat less 
disruptive than other substance use. For example, among methadone-maintained patients, 
cannabis use has relatively few deleterious effects on outcome (28) and is therefore often 
tolerated by opioid treatment programs. However, the adherence data have not been 
consistent and several studies have reported worse adherence among recent cannabis users 
(29–31). One explanation might be that there may be different populations of cannabis users. 
In one interesting study of patients in Northern California, the lack of an overall association 
between cannabis use and adherence masked important sub-sample differences. Cannabis 
users who did not complain of nausea had lower adherence than non-users, but cannabis 
users who complained of nausea had higher adherence than patients who did not use 
cannabis (27).
When all the substances were added to our analyses, it was not possible to identify an effect 
of a specific substance other than heroin. To a large extent, the variance in adherence 
accounted for by other substances overlaps among substances. This shared variance may 
reflect common features of people who use different substances such as a lack of skills and 
knowledge to adhere regularly (32), or impairment that negatively impacts adherence on 
days when substances were used (33). It is also possible that a confounding variable such as 
depression is associated with both non-adherence and substance use.
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There are limitations to this analysis that may have made it less able to detect effects of 
specific drugs. Substance use data were self-reported, and patients may have underestimated 
the extent of use (34). The association between alcohol use and adherence may have been 
stronger if data concerning quantity of alcohol use had been available instead of just 
frequency, as heavy drinking has been more strongly associated with non-adherence than 
drinking fewer drinks per day (35, 36). The summary variables mask the heterogeneity of 
how participants were asked questions and what time-frame was covered, thus adding noise 
to the signal of substance use.
Nevertheless, delineating the relationship between recent substance use and adherence has 
treatment implications. Knowing which substances are associated with non-adherence 
suggests where attention should be focused. These data suggest that it is important to 
address use of a variety of substances of abuse, although not necessarily cannabis, to 
understand non-adherence.
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